1080 related articles for article (PubMed ID: 27793564)
1. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
2. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
3. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
4. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
5. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
6. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
Goulis I; Karatapanis S; Akriviadis E; Deutsch M; Dalekos GN; Raptopoulou-Gigi M; Mimidis K; Germanidis G; Drakoulis C; Triantos C; Zintzaras E; Bakalos G; Papatheodoridis G
Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
[TBL] [Abstract][Full Text] [Related]
7. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
10. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
12. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
[TBL] [Abstract][Full Text] [Related]
13. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
14. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.
Rijckborst V; Hansen BE; Ferenci P; Brunetto MR; Tabak F; Cakaloglu Y; Lanza AG; Messina V; Iannacone C; Massetto B; Regep L; Colombo M; Janssen HLA; Lampertico P
J Hepatol; 2012 May; 56(5):1006-1011. PubMed ID: 22245886
[TBL] [Abstract][Full Text] [Related]
15. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
16. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
17. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
[TBL] [Abstract][Full Text] [Related]
18. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
19. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W
Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063
[TBL] [Abstract][Full Text] [Related]
20. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
